The snake venom peptide Bj-PRO-7a is a M1 muscarinic acetylcholine receptor agonist

Cytometry Part A

Volumn 79 A, Issue 1, 2011, Pages 77-83

  Negraes, Priscilla D ^a,b   Lameu, Claudiana ^a,b   Hayashi, Mirian A F ^c   Melo, Robson L ^b   Camargo, Antônio C M ^a,b   Ulrich, Henning ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bj PRO 7a; M1 agonist; Muscarinic receptor; Proline rich peptide from Bothrops jararaca

Indexed keywords

MUSCARINIC M1 RECEPTOR; OLIGOPEPTIDE; RECOMBINANT PROTEIN; SNAKE VENOM;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BIOSYNTHESIS; CALCIUM SIGNALING; CHEMISTRY; CHO CELL; CRICETULUS; DRUG POTENTIATION; HAMSTER; RAT; SNAKE;

AMINO ACID SEQUENCE; ANIMALS; BOTHROPS; CALCIUM SIGNALING; CHO CELLS; CRICETINAE; CRICETULUS; CROTALID VENOMS; OLIGOPEPTIDES; RATS; RECEPTOR, MUSCARINIC M1; RECOMBINANT PROTEINS;

EID: 78650433231     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.20963     Document Type: Article

References (49)

1. Ondetti MA, Cushman DW. Enzymes of the renin-angiotensin system and their inhibitors. Ann Rev Biochem 1982; 51: 283-308.
2. Smith CG, Vane JR. The discovery of captopril. FASEB J 2003; 17: 788-789.
3. Ferreira SH, Rocha e Silva M. Potentiation of bradykinin and eledoisin by BPF (bradykinin potentiating factor) from Bothrops jararaca venom. Experientia 1965; 21: 347-349.
4. Ferreira SH, Bartelt DC, Greene LJ. Isolation of bradykinin potentiating peptides from Bothrops jararaca venom. Biochemistry 1970; 13: 2583-2593.
5. Collier JG, Robinson BF, Vane JR. Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (B.P.P. 9a or SQ 20, 881) which inhibits converting enzyme. Lancet 1973; 1: 72-74.
6. Johnson JG, Black WD, Vukovich RA, Hatch FEJr, Friedman BI, Blackwell CF, Shenouda AN, Share L, Shade RE, Acchiardo SR, Muirhead EE. Treatment of patients with severe hypertension by inhibition of converting enzyme. Clin Sci Mol Med 1975; 48: 53s-56s.
7. Hayashi MA, Camargo AC. The bradykinin-potentiating peptides from venom gland and brain of Bothrops jararaca contain highly site specific inhibitors of the somatic angiotensin-converting enzyme. Toxicon 2005; 45: 1163-1170.
8. Ianzer D, Santos RA, Etelvino GM, Xavier CH, de Almeida Santos J, Mendes EP, Machado LT, Prezoto BC, Dive V, de Camargo AC. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE independent mechanisms? New insights from proline-rich peptides of Bothrops jararaca. J Pharmacol Exp Ther 2007; 322: 795-805.
9. Lameu C, Hayashi MA, Guerreiro JR, Oliveira EF, Lebrun I, Pontieri V, Morais KL, Camargo AC, Ulrich H. The central nervous system as target for antihypertensive actions of a proline-rich peptide from Bothrops jararaca venom. Cytometry Part A 2010; 77A: 220-230.
10. Ianzer D, Konno K, Marques-Porto R, Portaro FCV, Stöcklin R, Martins de Camargo AC, Pimenta DC. Identification of five new bradykinin potentiating peptides (Bj-PRO-7As) from Bothrops jararaca crude venom by using electrospray ionization tandem mass spectrometry after a two-step liquid chromatography. Peptides 2004; 25: 1085-1092.
11. Hayashi MA, Murbach AF, Ianzer D, Portaro FC, Prezoto BC, Fernandes BL, Silveira PF, Silva CA, Pires RS, Britto LR, Dive V, Camargo AC. The C-type natriuretic peptide precursor of snake brain contains highly specific inhibitors of the angiotensin-converting enzyme. J Neurochem 2003; 85: 969-977.
12. Murayama N, Hayashi MA, Ohi H, Ferreira LA, Fernades BL, Yamane T, Camargo ACM. Cloning and sequence analysis of a Bothrops jararaca cDNA encoding a precursor of seven bradykinin-potentiating peptides and a C-type natriuretic peptide. Proc Natl Acad Sci U S A 1997; 94: 1189-1193.
13. Lauder JM. Neurotransmitters as growth regulatory signals: Role of receptors and second messengers. Trends Neurosci 1993; 16: 233-240.
14. Liu J, Morrow AL, Devaud L, Grayson DR, Lauder JM. GABAA receptors mediate trophic effects of GABA on embryonic brainstem monoamine neurons in vitro. J Neurosci 1997; 17: 2420-2428.
15. Trujillo CA, Schwindt TT, Martins AH, Alves JM, Mello LE, Ulrich H. Novel perspectives of neural stem cell differentiation: From neurotransmitters to therapeutics. Cytometry Part A 2009; 75A: 38-53.
16. Villard E, Soubrier F. Molecular biology and genetics of the angiotensin-I-converting enzyme: Potential implications in cardiovascular diseases. Cardiovasc Res 1996; 32: 999-1007.
17. Kalaria RN, Homayoun P, Whitehouse PJ. Nicotinic cholinergic receptors associated with mammalian cerebral vessels. J Auton Nerv Syst 1994; 49: 3-7.
18. Hawkins BT, Egleton RD, Davis TP. Modulation of cerebral microvascular permeability by endothelial nicotinic acetylcholine receptors. Am J Physiol Heart Circ Physiol 2005; 289: 212-219.
19. Nery AA, Trujillo CA, Lameu C, Konno K, Oliveira V, Camargo AC, Ulrich H, Hayashi MA. A novel physiological property of snake bradykinin-potentiating peptides-reversion of MK-801 inhibition of nicotinic acetylcholine receptors. Peptides 2008; 29: 1708-1715.
20. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376.
21. Bruggmann D, Lips KS, Pfeil U, Haberberger RV, Kummer W. Multiple nicotinic acetylcholine receptor alpha-subunits are expressed in the arterial system of the rat. Histochem Cell Biol 2002; 118: 441-447.
22. Poller U, Nedelka G, Radke J, Pönicke K, Brodde OE. Age-dependent changes in cardiac muscarinic receptor function in healthy volunteers. J Am Coll Cardiol 1997; 29: 187-193.
23. Lazartigues E, Brefel-Courbon C, Tran MA, Montastruc JL, Rascol O. Spontaneously hypertensive rats cholinergic hyper-responsiveness: Central and peripheral pharmacological mechanisms. Br J Pharmacol 1999; 127: 1657-1665.
24. Hardouin SN, Richmond KN, Zimmerman A, Hamilton SE, Feigl EO, Nathanson NM. Altered cardiovascular responses in mice lacking the M(1) muscarinic acetylcholine receptor. J Pharmacol Exp Ther 2002; 301: 129-137.
25. Roux S, Zékri E, Rousseau B, Paternostre M, Cintrat JC, Fay N. Elimination and exchange of trifluoroacetate counter-ion from cationic peptides: A critical evaluation of different approaches. J Peptide Sci 2008; 14: 354-359.
26. Martins AH, Resende RR, Majumder P, Faria M, Casarini DE, Tarnok A, Colli W, Pesquero JB, Ulrich H. Neuronal differentiation of P19 embryonal carcinoma cells modulates kinin B2 receptor gene expression and function. J Biol Chem 2005; 280: 19576-19586.
27. Sykes DA, Dowling MR, Charlton SJ. Exploring the mechanism of agonist efficacy: A relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol 2009; 76: 543-551.
28. Martins AH, Alves JM, Trujillo CA, Schwindt TT, Barnabé GF, Motta FL, Guimaraes AO, Casarini DE, Mello LE, Pesquero JB, Ulrich H. Kinin-B2 receptor expression and activity during differentiation of embryonic rat neurospheres. Cytometry Part A 2008; 73A: 361-368.
29. Stewart JM, Ferreira SH, Greene LJ. Bradykinin potentiating peptide PCA-Lys-Trp-Ala-Pro: An inhibitor of the pulmonary inactivation of bradykinin and conversion of angiotensin I to II. Biochem Pharmacol 1971; 20: 1557-1567.
30. Black CE, Huang N, Neligan PC, Levine RH, Lipa JE, Lintlop S, Forrest CR, Pang CY. Effect of nicotine on vasoconstrictor and vasodilator responses in human skin vasculature. Am J Physiol Regul Integr Comp Physiol 2001; 281: 1097-1104.
31. Nery AA, Trujillo CA, Lameu C, Konno K, Oliveira V, Camargo ACM, Ulrich H, Hayashi MAF. Nicotinic acetylcholine receptors modulation by a snake toxin. J Mol Neurosci 2010; 40: 252-254.
32. Resende RR, Gomes KN, Adhikari A, Britto LR, Ulrich H. Mechanism of acetylcholine-induced calcium signaling during neuronal differentiation of P19 embryonal carcinoma cells in vitro. Cell Calcium 2008; 43: 107-121.
33. Parnas D, Heldman E, Branski L, Feinstein N, Linial M. Expression and localization of muscarinic receptors in P19-derived neurons. J Mol Neurosci 1998; 10: 17-29.
34. Racke K, Matthiesen S. The airway cholinergic system: Physiology and pharmacology. Pulm Pharmacol Ther 2004; 17: 181-198.
35. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000; 163: 495-529.
36. Terry AVJr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003; 306: 821-827.
37. Roman GC. Cholinergic dysfunction in vascular dementia. Curr Psychiatry Rep 2005; 7: 18-26.
38. Pan ZZ, Williams JT. Muscarine hyperpolarizes a subpopulation of neurons by activating an M2 muscarinic receptor in rat nucleus raphe magnus in vitro. J Neurosci 1994; 14: 1332-1338.
39. Tárnok A, Ulrich H. Characterization of pressure-induced calcium response in neuronal cell lines. Cytometry 2001; 43: 175-181.
40. Cushman DW, Cheung HS, Sabo EF, Ondetti MA. Design of potent competitive inhibitors of angiotensin-converting enzyme. Carbosyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 1977; 16: 5484-5491.
41. Cushman DW, Ondetti MA. Design of angiotensin converting enzyme inhibitors. Nat Med 1999; 5: 1110-1112.
42. Mullol J, Baraniuk JN, Logun C, Mérida M, Hausfeld J, Shelhamer JH, Kaliner MA. M1 and M3 muscarinic antagonists inhibit human nasal glandular secretion in vitro. J Appl Physiol 1992; 73: 2069-2073.
43. Kunitake A, Kunitake T, Stewart M. Differential modulation by carbachol of four separate excitatory afferent systems to the rat subiculum in vitro. Hippocampus 2004; 14: 986-999.
44. Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Egozi I, Sonego H, Marcovitch I, Brandeis R. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: Implications in future therapy. J Mol Neurosci 2003; 20: 349-356.
45. Heinrich JN, Butera JA, Carrick T, Kramer A, Kowal D, Lock T, Marquis KL, Pausch MH, Popiolek M, Sun SC, Tseng E, Uveges AJ, Mayer SC. Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol 2009; 605: 53-56.
46. Sadashiva CT, Chandra JN, Kavitha CV, Thimmegowda A, Subhash MN, Rangappa KS. Synthesis and pharmacological evaluation of novel N-alkyl/aryl substituted thiazolidinone arecoline analogues as muscarinic receptor 1 agonist in Alzheimer's dementia models. Eur J Med Chem 2009; 44: 4848-4854.
47. Budzik B, Garzya V, Shi D, Foley JJ, Rivero RA, Langmead CJ, Watson J, Wu Z, Forbes IT, Jin J. 2' Biaryl amides as novel and subtype selective M1 agonists. Part I: Identification, synthesis, and initial SAR. Bioorg Med Chem Lett 2010; 20: 3540-3544.
48. Eglen RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol 2006; 26: 219-233.
49. Davis AA, Fritz JJ, Wess J, Lah JJ, Levey AI. Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J Neurosci 2010; 30: 4190-4196.